Evaluation and multi-institutional validation of a novel urine biomarker lncRNA546 to improve the diagnostic specificity of prostate cancer in PSA gray-zone

Evaluation and multi-institutional validation of a novel urine biomarker lncRNA546 to improve the diagnostic specificity of prostate cancer in PSA gray-zone

Background and objectivesProstate specific antigen (PSA) is currently the most commonly used biomarker for prostate cancer diagnosis. However, when PSA is in the gray area of 4-10 ng/ml, the diagnostic specificity of prostate cancer is extremely low, leading to overdiagnosis in many clinically false...

Full description

Bibliographic Details
Main Authors: Fei Liu, Xiaolei Shi, Fangming Wang, Sujun Han, Dong Chen, Xu Gao, Linhui Wang, Qiang Wei, Nianzeng Xing, Shancheng Ren
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-08-01
Series:Frontiers in Oncology
Subjects:
prostatic neoplasms
biomarkers
urine
long non-coding RNA
PCA3
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.946060/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.946060/full

Similar Items